Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
Clinical trial NCT04179175 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04179175
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-18
- Primary completion
- 2023-05-26
- Enrollment
- 703
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.